Please assess the completion status of the following clinical trial:

Trial Title: Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60~* Ability to speak English~* Undergoing non-cardiac, non-neurologic surgical procedures; surgery scheduled to last \> 2 hours; due to be admitted to the hospital following surgery~Exclusion Criteria:~* Inmate of a correctional facility~* Scheduled to receive systemic chemotherapy between the time of the two cognitive testing sessions~* Known inability to undergo LPs due to anticoagulant use, severe anxiety, or other clinical contraindication known ahead of time.~* Inappropriate for study inclusion based on the judgement of the principal investigator.~* If a patient undergoes major head trauma that occurs between the times of the two cognitive testing sessions, then they will be withdrawn from the study.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CN-105 (Type: EXPERIMENTAL): Cohort 1: 50 Patients Dose of CN-105: 0.1 mg/kg~Cohort 2: 50 Patients Dose of CN-105: 0.5 mg/kg~Cohort 3: 50 Patients Dose of CN-105: 1 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Cohort 1: 17 Patients receiving placebo~Cohort 2: 17 Patients receiving placebo~Cohort 3: 17 Patients receiving placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).